Inari Medical (NARI) Receives a Buy from BTIG

In a report issued on June 24, Marie Thibault from BTIG maintained a Buy rating on Inari Medical (NARIResearch Report), with a price target of $100.00. The company’s shares closed last Friday at $71.14.

According to, Thibault is a 4-star analyst with an average return of 6.2% and a 27.2% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.

Currently, the analyst consensus on Inari Medical is a Strong Buy with an average price target of $100.50, a 43.5% upside from current levels. In a report issued on June 21, Piper Sandler also initiated coverage with a Buy rating on the stock with a $100.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $100.00 and a one-year low of $50.50. Currently, Inari Medical has an average volume of 762.5K.

Based on the recent corporate insider activity of 96 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NARI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.

Read More on NARI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More